Savara's Molgramostim Shows Sustained Efficacy in Long-Term aPAP Trial

Event summary

  • Savara presented long-term efficacy and safety data from the IMPALA-2 Phase 3 trial of molgramostim for autoimmune pulmonary alveolar proteinosis (aPAP) at the ATS 2026 International Conference.
  • The trial showed sustained improvements in pulmonary gas transfer and respiratory quality of life over 48 weeks of open-label treatment.
  • 94% of patients (151 out of 160) continued into the open-label period, with no discontinuations due to treatment-related adverse events.
  • Molgramostim demonstrated continuous improvement in DLco% and SGRQ scores, with placebo crossover patients showing significant improvements upon switching to molgramostim.

The big picture

Savara's positive long-term data for molgramostim reinforces its potential as a first-line treatment for aPAP, a rare and debilitating lung disease with limited therapeutic options. The high patient retention rate and sustained efficacy metrics suggest strong clinical validation, which could be pivotal for regulatory submissions and future market adoption. The results also highlight the importance of targeted therapies in rare respiratory diseases, an area of growing focus for biopharmaceutical companies.

What we're watching

Regulatory Pathway
Whether the sustained efficacy and safety data will accelerate molgramostim's regulatory approval process for aPAP.
Market Potential
The pace at which Savara can commercialize molgramostim if approved, given the rare disease landscape and unmet medical need.
Competitive Dynamics
How these results position molgramostim against potential competitors in the aPAP treatment space.